Additionally, UCP2-Ad administration dramatically increased the W/D ratio (Figure 2(c)) and protein amount (Figure 2(d)) in BALF after LPS treatment, indicating that UCP2-Ad aggravated alveolar-capillary barrier damage in ALI. This evidence concerns the gene UCP2 and acute respiratory distress syndrome.